---
layout: post
title: "海思科：签署利鲁唑口腔膜EXSERVAN许可和供应协议"
date: 2022-03-03 16:20:30 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002653" data-code="002653|0|2" data-code2="002653|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002653&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002653_0" data-code="K 002653|0|2" data-code2="K 002653|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>海思科(002653)3月3日晚间公告，公司与美国Aquestive签署了治疗肌萎缩侧索硬化症的利鲁唑口腔膜EXSERVAN的许可和供应协议。海思科将负责EXSERVAN在中国的注册和商业化活动。Aquestive将作为该产品的独家制造商和供应商。EXSERVAN尚需获得药监部门下发的药品注册批件后方能上市销售。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203032295884130>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)